Marcel Spaargaren

List of Publications by Year
in descending order

Source: https://exaly.com/author-pdf/3896883/publications.pdf

Version: 2024-02-01

97 papers	9,871 citations	57631 44 h-index	39575 94 g-index
101 all docs	101 docs citations	101 times ranked	12198 citing authors

#	Article	IF	Citations
1	Design and standardization of PCR primers and protocols for detection of clonal immunoglobulin and T-cell receptor gene recombinations in suspect lymphoproliferations: Report of the BIOMED-2 Concerted Action BMH4-CT98-3936. Leukemia, 2003, 17, 2257-2317.	3.3	2,788
2	The clinically active BTK inhibitor PCI-32765 targets B-cell receptorâ€“ and chemokine-controlled adhesion and migration in chronic lymphocytic leukemia. Blood, 2012, 119, 2590-2594.	0.6	493
3	EuroClonality/BIOMED-2 guidelines for interpretation and reporting of Ig/TCR clonality testing in suspected lymphoproliferations. Leukemia, 2012, 26, 2159-2171.	3.3	409
4	Differential Interaction of the Ras Family GTP-binding Proteins H-Ras, Rap1A, and R-Ras with the Putative Effector Molecules Raf Kinase and Ral-Guanine Nucleotide Exchange Factor. Journal of Biological Chemistry, 1996, 271, 6794-6800.	1.6	298
5	Illegitimate WNT signaling promotes proliferation of multiple myeloma cells. Proceedings of the National Academy of Sciences of the United States of America, 2004, 101, 6122-6127.	3.3	293
6	Significantly improved PCR-based clonality testing in B-cell malignancies by use of multiple immunoglobulin gene targets. Report of the BIOMED-2 Concerted Action BHM4-CT98-3936. Leukemia, 2007, 21, 207-214.	3.3	292
7	Bruton's Tyrosine Kinase and Phospholipase CÎ³2 Mediate Chemokine-Controlled B Cell Migration and Homing. Immunity, 2007, 26, 93-104.	6.6	262
8	Identification of the guanine nucleotide dissociation stimulator for Ral as a putative effector molecule of R-ras, H-ras, K-ras, and Rap.. Proceedings of the National Academy of Sciences of the United States of America, 1994, 91, 12609-12613.	3.3	251
9	Cell surface proteoglycan syndecan-1 mediates hepatocyte growth factor binding and promotes Met signaling in multiple myeloma. Blood, 2002, 99, 1405-1410.	0.6	235
10	Powerful strategy for polymerase chain reaction-based clonality assessment in T-cell malignancies Report of the BIOMED-2 Concerted Action BHM4 CT98-3936. Leukemia, 2007, 21, 215-221.	3.3	222
11	The B Cell Antigen Receptor Controls Integrin Activity through Btk and PLCÎ³2. Journal of Experimental Medicine, 2003, 198, 1539-1550.	4.2	211
12	Heparan sulfate proteoglycan binding promotes APRIL-induced tumor cell proliferation. Cell Death and Differentiation, 2005, 12, 637-648.	5.0	204
13	Heparan Sulfate-modified CD44 Promotes Hepatocyte Growth Factor/Scatter Factor-induced Signal Transduction through the Receptor Tyrosine Kinase c-Met. Journal of Biological Chemistry, 1999, 274, 6499-6506.	1.6	198
14	Egress of CD19+CD5+ cells into peripheral blood following treatment with the Bruton tyrosine kinase inhibitor ibrutinib in mantle cell lymphoma patients. Blood, 2013, 122, 2412-2424.	0.6	185
15	High prevalence of oncogenic MYD88 and CD79B mutations in diffuse large B-cell lymphomas presenting at immune-privileged sites. Blood Cancer Journal, 2013, 3, e139-e139.	2.8	164
16	Deletion of the WNT Target and Cancer Stem Cell Marker CD44 in Apc(Min/+) Mice Attenuates Intestinal Tumorigenesis. Cancer Research, 2008, 68, 3655-3661.	0.4	163
17	Lymphoma dissemination: the other face of lymphocyte homing. Blood, 2007, 110, 3102-3111.	0.6	157
18	The hepatocyte growth factor/Met pathway controls proliferation and apoptosis in multiple myeloma. Leukemia, 2003, 17, 764-774.	3.3	145

#	Article	IF	Citations
19	Aberrant Wnt signaling in multiple myeloma: molecular mechanisms and targeting options. Leukemia, 2019, 33, 1063-1075.	3.3	119
20	Stem cell CD44v isoforms promote intestinal cancer formation in Apc(min) mice downstream of Wnt signaling. Oncogene, 2014, 33, 665-670.	2.6	116
21	Primary Follicular Lymphoma of the Small Intestine. American Journal of Pathology, 2003, 162, 105-113.	1.9	96
22	The hepatocyte growth factor/ met pathway in development, tumorigenesis, and B-cell differentiation. Advances in Cancer Research, 2000, 79, 39-90.	1.9	95
23	High prevalence of oncogenic MYD88 and CD79B mutations in primary testicular diffuse large B-cell lymphoma. Leukemia, 2014, 28, 719-720.	3.3	91
24	FOXP1 directly represses transcription of proapoptotic genes and cooperates with NF-Î¹B to promote survival of human B cells. Blood, 2014, 124, 3431-3440.	0.6	86
25	Factor VIIa/Tissue Factor-induced Signaling via Activation of Src-like Kinases, Phosphatidylinositol 3-Kinase, and Rac. Journal of Biological Chemistry, 2000, 275, 28750-28756.	1.6	85
26	Association of RACK1 and PKCÎ² with the common Î²-chain of the IL-5/IL-3/GM-CSF receptor. Oncogene, 1999, 18, 5126-5130.	2.6	81
27	Functional analysis of HGF/MET signaling and aberrant HGF-activator expression in diffuse large B-cell lymphoma. Blood, 2006, 107, 760-768.	0.6	80
28	Ibrutinib and idelalisib synergistically target BCR-controlled adhesion in MCL and CLL: a rationale for combination therapy. Blood, 2015, 125, 2306-2309.	0.6	79
29	Rab5 Induces Rac-independent Lamellipodia Formation and Cell Migration. Molecular Biology of the Cell, 1999, 10, 3239-3250.	0.9	77
30	Human sprouty 4, a new ras antagonist on 5q31, interacts with the dual specificity kinase TESK1. FEBS Journal, 2002, 269, 2546-2556.	0.2	76
31	Expression of c-Met and Heparan-Sulfate Proteoglycan Forms of CD44 in Colorectal Cancer. American Journal of Pathology, 2000, 157, 1563-1573.	1.9	75
32	Syndecan-1 promotes Wnt/Î²-catenin signaling in multiple myeloma by presenting Wnts and R-spondins. Blood, 2018, 131, 982-994.	0.6	68
33	The Ras-related protein R-ras interacts directly with Raf-1 in a GTP-dependent manner. Biochemical Journal, 1994, 300, 303-307.	1.7	62
34	c-Cbl Is Involved in Met Signaling in B Cells and Mediates Hepatocyte Growth Factor-Induced Receptor Ubiquitination. Journal of Immunology, 2002, 169, 3793-3800.	0.4	57
35	Characterization and identification of an epidermal-growth-factor-activated phospholipase A2. Biochemical Journal, 1992, 287, 37-43.	1.7	56
36	MYD88 mutations identify a molecular subgroup of diffuse large B-cell lymphoma with an unfavorable prognosis. Haematologica, 2020, 105, 424-434.	1.7	55

#	Article	IF	Citations
37	Multiple myeloma cells catalyze hepatocyte growth factor (HGF) activation by secreting the serine protease HGF-activator. Blood, 2004, 104, 2172-2175.	0.6	54
38	Tubular epithelial syndecan-1 maintains renal function in murine ischemia/reperfusion and human transplantation. Kidney International, 2012, 81, 651-661.	2.6	54
39	Epidermal Growth Factor (EGF) Induces Serine Phosphorylation-Dependent Activation and Calcium-Dependent Translocation of the Cytosolic Phospholipase A2. FEBS Journal, 1995, 231, 593-601.	0.2	53
40	Transcriptional Silencing of the Wnt-Antagonist Dickkopf-1 (DKK1) by Promoter Methylation Unleashes Aberrant Wnt Signaling In Advanced Multiple Myeloma. Blood, 2010, 116, 1919-1919.	0.6	53
41	Targeting EXT1 reveals a crucial role for heparan sulfate in the growth of multiple myeloma. Blood, 2010, 115, 601-604.	0.6	50
42	Infection and transmission of SARSâ€CoVâ€2 depend on heparan sulfate proteoglycans. EMBO Journal, 2021, 40, e106765.	3.5	50
43	Disruption of heparan sulfate proteoglycan conformation perturbs B-cell maturation and APRIL-mediated plasma cell survival. Blood, 2011, 117, 6162-6171.	0.6	48
44	MET Signaling Mediates Intestinal Crypt-Villus Development, Regeneration, and Adenoma Formation and Is Promoted by Stem Cell CD44 Isoforms. Gastroenterology, 2017, 153, 1040-1053.e4.	0.6	48
45	Heparan sulfate proteoglycans in the control of <scp>B</scp> cell development and the pathogenesis of multiple myeloma. FEBS Journal, 2013, 280, 2180-2193.	2.2	47
46	Regulation of Cytokine Signaling by B Cell Antigen Receptor and Cd40-Controlled Expression of Heparan Sulfate Proteoglycans. Journal of Experimental Medicine, 2000, 192, 1115-1124.	4.2	46
47	The small GTPase Ral mediates SDF-1â€“induced migration of B cells and multiple myeloma cells. Blood, 2008, 111, 3364-3372.	0.6	43
48	The forkhead transcription factor FOXP1 represses human plasma cell differentiation. Blood, 2015, 126, 2098-2109.	0.6	42
49	Illegitimate WNT Pathway Activation by Î²-Catenin Mutation or Autocrine Stimulation in T-Cell Malignancies. Cancer Research, 2008, 68, 6969-6977.	0.4	41
50	Transcriptional Silencing of the Wnt-Antagonist DKK1 by Promoter Methylation Is Associated with Enhanced Wnt Signaling in Advanced Multiple Myeloma. PLoS ONE, 2012, 7, e30359.	1.1	41
51	The hypoxia target adrenomedullin is aberrantly expressed in multiple myeloma and promotes angiogenesis. Leukemia, 2013, 27, 1729-1737.	3.3	41
52	Tubulointerstitial heparan sulfate proteoglycan changes in human renal diseases correlate with leukocyte influx and proteinuria. American Journal of Physiology - Renal Physiology, 2008, 294, F253-F263.	1.3	39
53	Hepatocyte growth factor triggers signaling cascades mediating vascular smooth muscle cell migration. Biochemical and Biophysical Research Communications, 2002, 298, 80-86.	1.0	37
54	Aberrantly expressed LGR4 empowers Wnt signaling in multiple myeloma by hijacking osteoblast-derived R-spondins. Proceedings of the National Academy of Sciences of the United States of America, 2017, 114, 376-381.	3.3	37

#	Article	IF	Citations
55	Interaction of Epidermal growth factor receptors with the cytoskeleton is related to receptor clustering. Journal of Cellular Physiology, 1990, 145, 365-375.	2.0	36
56	N-cadherin-mediated interaction with multiple myeloma cells inhibits osteoblast differentiation. Haematologica, 2011, 96, 1653-1661.	1.7	36
57	Loss of CYLD expression unleashes Wnt signaling in multiple myeloma and is associated with aggressive disease. Oncogene, 2017, 36, 2105-2115.	2.6	34
58	The B Cell Antigen Receptor Controls AP-1 and NFAT Activity through Ras-Mediated Activation of Ral. Journal of Immunology, 2007, 178, 1405-1414.	0.4	31
59	Ibrutinib and idelalisib target B cell receptor- but not CXCL12/CXCR4-controlled integrin-mediated adhesion in Waldenstrom macroglobulinemia. Haematologica, 2016, 101, e111-e115.	1.7	30
60	BTK inhibitors in chronic lymphocytic leukemia: a glimpse to the future. Oncogene, 2015, 34, 2426-2436.	2.6	29
61	The HGF/MET pathway as target for the treatment of multiple myeloma and B-cell lymphomas. Biochimica Et Biophysica Acta: Reviews on Cancer, 2010, 1806, 208-219.	3.3	28
62	Cell lines generated from a chronic lymphocytic leukemia mouse model exhibit constitutive Btk and Akt signaling. Oncotarget, 2017, 8, 71981-71995.	0.8	27
63	WNT signaling controls expression of pro-apoptotic BOK and BAX in intestinal cancer. Biochemical and Biophysical Research Communications, 2011, 406, 1-6.	1.0	26
64	Hepatocyte growth factor/MET and CD44 in colorectal cancer: partners in tumorigenesis and therapy resistance. Biochimica Et Biophysica Acta: Reviews on Cancer, 2020, 1874, 188437.	3.3	26
65	Impaired Lymphoid Organ Development in Mice Lacking the Heparan Sulfate Modifying Enzyme Glucuronyl C5-Epimerase. Journal of Immunology, 2010, 184, 3656-3664.	0.4	25
66	Follicular Dendritic Cells Catalyze Hepatocyte Growth Factor (HGF) Activation in the Germinal Center Microenvironment by Secreting the Serine Protease HGF Activator. Journal of Immunology, 2005, 175, 2807-2813.	0.4	24
67	Stimulated plasmacytoid dendritic cells impair human T-cell development. Blood, 2006, 108, 3792-3800.	0.6	24
68	CD44 Expression in Intestinal Epithelium and Colorectal Cancer Is Independent of p53 Status. PLoS ONE, 2013, 8, e72849.	1.1	23
69	AKT signaling restrains tumor suppressive functions of FOXO transcription factors and GSK3 kinase in multiple myeloma. Blood Advances, 2020, 4, 4151-4164.	2.5	20
70	R-Ras Alters Ca2+ Homeostasis by Increasing the Ca2+ Leak across the Endoplasmic Reticular Membrane. Journal of Biological Chemistry, 2003, 278, 13672-13679.	1.6	18
71	The small FOXP1 isoform predominantly expressed in activated B cell-like diffuse large B-cell lymphoma and full-length FOXP1 exert similar oncogenic and transcriptional activity in human B cells. Haematologica, 2017, 102, 573-583.	1.7	18
72	The pan phosphoinositide 3-kinase/mammalian target of rapamycin inhibitor SAR245409 (voxtalisib/XL765) blocks survival, adhesion and proliferation of primary chronic lymphocytic leukemia cells. Leukemia, 2016, 30, 337-345.	3.3	17

#	Article	IF	Citations
73	The CXCL12gamma chemokine immobilized by heparan sulfate on stromal niche cells controls adhesion and mediates drug resistance in multiple myeloma. Journal of Hematology and Oncology, 2021, 14, 11.	6.9	15
74	MET Signaling Overcomes Epidermal Growth Factor Receptor Inhibition in Normal and Colorectal Cancer Stem Cells Causing Drug Resistance. Gastroenterology, 2019, 157, 1153-1155.e1.	0.6	14
75	Identification of the SRC-family tyrosine kinase HCK as a therapeutic target in mantle cell lymphoma. Leukemia, 2021, 35, 881-886.	3.3	14
76	Syndecan-1 and stromal heparan sulfate proteoglycans: key moderators of plasma cell biology and myeloma pathogenesis. Blood, 2021, 137, 1713-1718.	0.6	14
77	The anaphase-promoting complex/cyclosome: a new promising target in diffuse large B-cell lymphoma and mantle cell lymphoma. British Journal of Cancer, 2019, 120, 1137-1146.	2.9	12
78	Diffuse large B cell lymphomas relapsing in the CNS lack oncogenic MYD88 and CD79B mutations. Blood Cancer Journal, 2014, 4, e266-e266.	2.8	11
79	Antibody-induced activation of the epidermal growth factor receptor tyrosine kinase requires the presence of detergent. Biochemical and Biophysical Research Communications, 1990, 171, 882-889.	1.0	10
80	Tipping the balance: toward rational combination therapies to overcome venetoclax resistance in mantle cell lymphoma. Leukemia, 2022, 36, 2165-2176.	3.3	8
81	Possible Mechanisms Of Resistance To The Novel BH3-Mimetic ABT-199 In In Vitro Lymph Node Models Of CLL â€“ The Role Of Abl and Btk. Blood, 2013, 122, 4188-4188.	0.6	6
82	Redirecting T-cell Activity with Anti-BCMA/Anti-CD3 Bispecific Antibodies in Chronic Lymphocytic Leukemia and Other B-cell Lymphomas. Cancer Research Communications, 2022, 2, 330-341.	0.7	6
83	Targeting cell adhesion and homing as strategy to cure WaldenstrÃ¶m's macroglobulinemia. Best Practice and Research in Clinical Haematology, 2016, 29, 161-168.	0.7	5
84	Immune evasion in primary testicular and central nervous system lymphomas: HLA loss rather than 9p24.1/PD-L1/PD-L2 alterations. Blood, 2021, 138, 1194-1197.	0.6	5
85	Lymphoma spread? Target CD47-SIRPÎ±!. Blood, 2011, 118, 4762-4764.	0.6	4
86	A loss-of-adhesion CRISPR-Cas9 screening platform to identify cell adhesion-regulatory proteins and signaling pathways. Nature Communications, 2022, 13, 2136.	5.8	4
87	Instant conditional transgenesis in the mouse hematopoietic compartment. Journal of Immunological Methods, 2008, 339, 259-263.	0.6	3
88	Combined Inhibition of mTOR and DNA-PK Blocks Survival, Adhesion, Proliferation and Chemoresistance in Primary Chronic Lymphocytic Leukemia (CLL) Cells. Blood, 2014, 124, 1981-1981.	0.6	3
89	Mapping the Targets of Dasatinib in Chronic Lymphocytic Leukemia Reveals Distinct Roles for Abl and Btk in Drug Resistance and Adhesion, and Explains Clinical Effects On Lymph Node Reduction. Blood, 2012, 120, 3900-3900.	0.6	2
90	Ibrutinib for AML? Check CD117 (KIT)!. Lancet Haematology,the, 2015, 2, e180-e181.	2.2	1

#	Article	IF	Citations
91	Targeting EXT-1 Reveals a Crucial Role of Heparan Sulfate in the Growth of Multiple Myeloma.. Blood, 2009, 114, 1830-1830.	0.6	1
92	Egress of CD19+CD5+ Cells Into Peripheral Blood Following Treatment with the Bruton Tyrosine Kinase Inhibitor, PCI-32765, in Mantle Cell Lymphoma Patients. Blood, 2011, 118, 954-954.	0.6	1
93	Combined Inhibition of Phosphatidylinositol 3-Kinase (PI3K) Isoform Î± and Î´ By the Pan-Class I PI3K Inhibitor SAR245409 (XL765) in Primary Chronic Lymphocytic Leukemia Cells Blocks Survival, Adhesion and Proliferation. Blood, 2014, 124, 4691-4691.	0.6	1
94	Aberrant Wnt signaling in multiple myeloma: molecular mechanisms and targeting options. Clinical Lymphoma, Myeloma and Leukemia, 2019, 19, e108.	0.2	0
95	Syndecan-1 and stromal HSPGs: key moderators of communication between myeloma plasma cells and the bone marrow niche. Clinical Lymphoma, Myeloma and Leukemia, 2019, 19, e96-e97.	0.2	0
96	Dimerization Activates the Epidermal Growth Factor Receptor Tyrosine Kinase. , 1991, , 45-58.		0
97	General Mechanistic Patterns of Signal Transduction Across Membranes. , 0, , 1-59.		0